ReviewJournal of neurogastroenterology and motility2014
New and future drug development for gastroesophageal reflux disease.
Review in Journal of neurogastroenterology and motility, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05050188 (A Phase I, Randomized, Double-blind, Placebo- and Positive-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics), which is not on this map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I, Randomized, Double-blind, Placebo- and Positive-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of H008 (Carenoprazan Hydrochloride Tablets) in Healthy Volunteers
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Systematic review and meta-analysis of controlled and prospective cohort efficacy studies of endoscopic radiofrequency for treatment of gastroesophageal reflux disease.Surgical endoscopy · 2017Pooled it
- Trial
- Effect of food on the pharmacokinetics of YH4808, a potassium-competitive acid blocker, after single- and multiple-oral dosing in healthy subjects.European journal of clinical pharmacology · 2018Trial
- Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.World journal of gastroenterology · 2018Trial
- Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.Alimentary pharmacology & therapeutics · 2016Trial
- Effects of acotiamide on esophageal motor function and gastroesophageal reflux in healthy volunteers.BMC gastroenterology · 2015Trial
- Article
- In Vitro Metabolism and Transport Characteristics of Zastaprazan.Pharmaceutics · 2024Article
- Quantitative dose-response analysis untangles host bottlenecks to enteric infection.Nature communications · 2023Article
- Proton-Pump Inhibitors Suppress T Cell Response by Shifting Intracellular Zinc Distribution.International journal of molecular sciences · 2023Article
- Bridge Swallowing Exercise for Gastroesophageal Reflux Disease Symptoms: A Pilot Study.Progress in rehabilitation medicine · 2022Article
- The early therapeutic response at 2 weeks is a crucial predictor of proton pump inhibitor-refractory gastroesophageal reflux disease.Esophagus : official journal of the Japan Esophageal Society · 2021Article
- The effect of adding duloxetine to lansoprazole on symptom and quality of life improvement in patients with gastroesophageal reflux diseases: A randomized double-blind clinical trial.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2021Article
- Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative Against SARS-CoV2: An In Silico Analysis.Biomolecules · 2020Article
- Novel Therapies for Gastroesophageal Reflux Disease: Beyond Proton Pump Inhibitors.Current gastroenterology reports · 2020Review
- Esophageal Motor Dysfunctions in Gastroesophageal Reflux Disease and Therapeutic Perspectives.Journal of neurogastroenterology and motility · 2019Review
- Comparison of pharmacokinetic characteristics of two Tegoprazan (CJ-12420) formulations in healthy male subjects.Translational and clinical pharmacology · 2019Article
- Effects of Shugan Hewei Granule on Depressive Behavior and Protein Expression Related to Visceral Sensitivity in a Rat Model of Nonerosive Reflux Disease.Evidence-based complementary and alternative medicine : eCAM · 2019Article
- Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?World journal of gastrointestinal pharmacology and therapeutics · 2018Review
- Pathophysiology of Potassium-competitive Acid Blocker-refractory Gastroesophageal Reflux and the Potential of Potassium-competitive Acid Blocker Test.Journal of neurogastroenterology and motility · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medical therapy remains the most popular treatment for gastroesophageal reflux disease (GERD). Whilst interest in drug development for GERD has declined over the last few years primarily due to the conversion of most proton pump inhibitor (PPI)'s to generic and over the counter compounds, there are still numerous areas of unmet needs in GERD. Drug development has been focused on potent histamine type 2 receptor antagonist's, extended release PPI's, PPI combination, potassium-competitive acid blockers, transient lower esophageal sphincter relaxation reducers, prokinetics, mucosal protectants and esophageal pain modulators. It is likely that the aforementioned compounds will be niched for specific areas of unmet need in GERD, rather than compete with the presently available anti-reflux therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.